Try our beta test site
13 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND bendamustine [TREATMENT] | Open Studies | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma
Condition: Follicular Lymphoma
Intervention: Drug: Rituximab, bendamustine
2 Recruiting A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Condition: Lymphoma, Mantle Cell
Interventions: Drug: Acalabrutinib in combination with bendamustine and rituximab;   Drug: Placebo in combination with bendamustine and rituximab
3 Recruiting Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A);   Drug: Bendamustine infusion (Arm B)
4 Recruiting A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
5 Recruiting A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ACP-196;   Drug: Rituximab;   Drug: Idelalisib;   Drug: Bendamustine
6 Recruiting Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-Bendamustine for Relapsed/Refractory FL Patients
Condition: Lymphoma, Follicular
Interventions: Drug: R2-MANT;   Drug: R-MANT
7 Recruiting A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
Condition: Indolent B-cell NHL
Interventions: Drug: Bendamustine IV;   Other: Treatment of Physicians Choice
8 Recruiting A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment
Condition: Chronic Lymphocytic Leukaemia
Interventions: Drug: Ofatumumab;   Drug: Chlorambucil;   Drug: Bendamustine
9 Recruiting Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma
Condition: Follicular Non-Hodgkin's Lymphoma
Interventions: Drug: R-CHOP or R-bendamustine;   Drug: Observation;   Drug: Maintenance weekly x4;   Drug: Ibritumomab Tiuxetan + Maintenance;   Drug: Standard Maintenance
10 Recruiting Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Copanlisib (BAY 80-6946);   Drug: Placebo;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Bendamustine;   Drug: Prednisone
11 Recruiting Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Venetoclax;   Biological: Obinutuzumab;   Drug: Ibrutinib
12 Recruiting Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Biological: Avelumab;   Biological: Utomilumab;   Biological: Rituximab;   Other: Azacitidine;   Drug: Bendamustine;   Drug: Gemcitabine;   Drug: Oxaliplatin
13 Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Conditions: Follicular Lymphomas;   Immunocytomas;   Marginal Zone Lymphomas;   Mantle-Cell Lymphomas;   Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Rituximab / observation

Study has passed its completion date and status has not been verified in more than two years.